Open Access Research article

CHD1L Protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival

Wei-Peng He1, Juan Zhou1, Mu-Yan Cai2, Xiang-Shen Xiao2, Yi-Ji Liao2, Hsiang-Fu Kung3, Xin-Yuan Guan2, Dan Xie2 and Guo-Fen Yang1*

Author Affiliations

1 Department of Gynecology, the First Affiliated Hospital, Sun Yat-Sen University, No. 78, Zhongshan Road II, 510080, Guangzhou, China

2 State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University, No. 651, Dongfeng Road East, 510060, Guangzhou, China

3 Department of Oncology, the University of Hong Kong, Hong Kong, China

For all author emails, please log on.

BMC Cancer 2012, 12:437  doi:10.1186/1471-2407-12-437

Published: 29 September 2012

Abstract

Background

Our recent studies suggested that the chromodomain helicase DNA binding protein 1-like (CHD1L) gene plays an oncogenic role in human hepatocellular carcinoma. However, the status of CHD1L protein expression in ovarian cancer and its clinical/prognostic significance are obscure.

Methods

In this study, immunohistochemistry (IHC) for CHD1L was performed on a tissue microarray (TMA) containing 102 primary ovarian carcinomas and 44 metastatic lesions (omental metastasis). Receiver-operator curve (ROC) analysis was used to evaluate patients’ survival status.

Results

There is an augmented tendency of CHD1L expression in ovarian carcinoma metastasis than in primary lesions (P<0.05). A significant association was found between positive expression of CHD1L and tumors histological type (P <0.05). By univariate survival analysis of the ovarian carcinoma cohorts, positive expression of CHD1L was significantly correlated with shortened patient survival (mean 66.7 months versus 97.4 months, P<0.05). Moreover, CHD1L expression was evaluated to be a significant and independent prognostic factor in multivariate analysis (P<0.05).

Conclusions

These findings provide evidence that positive expression of CHD1L protein is significantly correlated with the metastasis proceeding of ovarian carcinoma, and CHD1L protein expression, as examined by IHC, may act as a novel prognostic biomarker for patients with ovarian carcinoma.